- Policy
- The government are in full swing discussing support
- by Lee, Jeong-Hwan Nov 24, 2022 05:50am
- The ruling party and the government's move to expand access to patients with severe and rare diseases, which was President Yoon Suk Yeol's presidential pledge, is notable. On the 21st, the People's Power, the Ministry of Health and Welfare, and the Ministry of Strategy and Finance will hold a policy meeting at the National Assembly to prepare
- Policy
- Gov’t to increase drug price reference countries
- by Lee, Tak-Sun Nov 23, 2022 06:04am
- The Health Insurance Review and Assessment Service made a preannouncement of a revision plan to expand the number of reference countries used to evaluate new drugs from 7 to 9 (US, UK, Germany, France, Italy, Switzerland, Japan, Canada, Australia·A9). After opinion inquiries, the revised plan will take effect in January next year. Althou
- InterView
- The key to treating stroke tx is preventing the recurrence
- by Kim, Jin-Gu Nov 23, 2022 06:04am
- Stroke is a battle against time. Whether the blood vessels in the brain are blocked (brain infarction) or burst (brain hemorrhage), blood should be supplied to the brain normally within a short period of time. The medical community explains that the golden time of stroke is 4.5 hours. This means that the problem can be solved only when the sy
- Policy
- MFDS recruits companies to develop 6 National Essential Drug
- by Lee, Hye-Kyung Nov 23, 2022 06:04am
- The government is busy recruiting institutions to develop domestic manufacturing technology for items that are heavily dependent on imports and have unstable supply to achieve self-sufficiency of national essential medicines. The Ministry of Food and Drug Safety had recently selected 11 products, including 5 raw materials and 6 finished prod
- Policy
- Forxiga Prodrug will be reimbursed for five months
- by Lee, Tak-Sun Nov 23, 2022 06:04am
- Prodrug of Forxiga, an SGLT-2 diabetes treatment drug that Dong-A ST succeeded in avoiding patents through the development of drugs, will be listed on the 1st of next month. It is five months before the expiration of the patent. Earlier this month, it was possible because it succeeded in avoiding the duration of the material patent, which end
- Company
- Kadcyla can be prescribed after registering benefit
- by Eo, Yun-Ho Nov 23, 2022 06:04am
- According to related industries, anticancer drugs such as ADC and Antibody-drug conjugate Kadcyla and CDK4/600 inhibitor Verzenio are entering the early breast cancer area in Korea. Kadcyla was already listed on the insurance benefit list in July, and the actual prescription began. The drug, which was used for the second or more treatment of
- Company
- Imjudo is expected to be introduced in Korea
- by Eo, Yun-Ho Nov 23, 2022 06:03am
- Another immuno-cancer drug with CTLA-4 inhibitory mechanism is expected to be introduced in Korea. According to related industries, AstraZeneca Korea has submitted an application for domestic permission for CTLA-4 inhibitor Imjudo, a partner in combination therapy for PD-L1 inhibitor Impinzi. The combination therapy of Impinzi and Imjudo was
- Company
- Attention focused on whether Luxturna will be reimb in Korea
- by Eo, Yun-Ho Nov 22, 2022 06:04am
- Discussions on expanding coverage of the one-shot gene therapy ‘Luxturna’ is not making much progress. Therefore, the industry’s eyes are on whether Novartis Korea’s Inherited Retinal Dystrophy (IRD) treatment Luxturna (voretigene neparvovec) will be presented as an agenda for deliberation by the Health Insurance Review and Assessmen
- Opinion
- [Reporter's view] Poor COVID-19 vaccine inducement
- by Nov 22, 2022 06:04am
- "Did you get the COVID-19 vaccine in winter? Mom and dad are the ones who should be vaccinated" The mother answered in a casual manner. "It's okay. I'm in my 60s, so I don't have to get it." "What are you talking about? You have hyperlipidemia. Get it right quickly." "It's okay. I think it'll pass lightly even if I get COVID-19." But will par
- Policy
- Reimb standards will be newly established for Coagadex
- by Kim, Jung-Ju Nov 22, 2022 06:04am
- Reimbursement standards for the hemophilia treatment Coagadex (Human coagulation factor X) that had been granted urgent introduction in Korea have been newly established. Also, oral eperisone hydrochloride as well as oral and ophthalmic solutions that include syrup and oral suspension forms of sodium alginate that were subject to reevalua
